Understanding resilience in Alzheimer's disease
Precision Medicine in Alzheimer's Disease: Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
This study is trying to see if measuring resilience in people with mild Alzheimer's can help predict how the disease will progress and improve their treatment options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 244 (estimated) |
| Ages | 50 Years to 90 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT06582199 on ClinicalTrials.gov |
What this trial studies
BioCogBankAD is focused on creating a clinical cohort of 244 patients with confirmed mild cognitive impairment or mild Alzheimer's disease to validate resilience markers identified in previous research. The study aims to enhance the prediction of disease progression and personalize treatment strategies by integrating resilience metrics with traditional biomarkers. Participants will undergo blood sampling and neuropsychological assessments to gather comprehensive data on their condition. This research addresses the significant challenge of predicting Alzheimer's disease progression in its early stages.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50-90 with a diagnosis of mild cognitive impairment or mild Alzheimer's disease and specific biomarker profiles.
Not a fit: Patients with other causes of dementia or those currently participating in other Alzheimer's therapeutic trials may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and management of Alzheimer's disease, enhancing patient care and outcomes.
How similar studies have performed: While there have been studies focusing on biomarkers in Alzheimer's disease, the integration of resilience metrics is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of AD according to IWG-2 2014 criteria * Age 50-90 year old * Affiliated or beneficiary of a social security scheme * MMSE ≥ 20 * Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs * Abnormal CSF phosphorylated and total Tau according to local cut-offs * Ability to pass neuropsychological assessments * Availability of a brain MRI with T1 volumetric sequence performed within 1 year Exclusion Criteria: * Other cause of dementia * Participation in an AD therapeutic clinical trial * Protected adults (including individual under guardianship by court order),
Where this trial is running
Paris
- Hôpital Cochin — Paris, France (Recruiting)
Study contacts
- Study coordinator: Olivier HANON, MD, PhD
- Email: olivier.hanon@aphp.fr
- Phone: + 1 44 08 33 81
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.